Citius Pharmaceuticals, Inc.

CTXR Nasdaq SEC CIK 1506251
Follow Citius Pharmaceuticals Weekly email: filings, results, news

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.5M
Net income −$11.9M −29.5% vs same quarter last year
EPS, diluted −$0.34 +57.5% vs same quarter last year
Operating cash flow −$8.7M −60.5% vs same quarter last year
Revenue by quarter
$3.9M
$1.7M
$1.5M
Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$30M−$20M−$10M$0$10MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$39.7M
FY24-−$39.4M
FY23-−$32.5M
FY22$90K−$33.6M
FY21$90K−$23.1M
FY20$90K−$17.5M
FY19$90K−$15.6M
FY18$75K−$12.5M
FY17$50K−$10.4M
FY16-−$8.3M
FY15-−$2.9M
FY14-−$737.7K
FY13$0−$1M
FY12$0−$22K
FY11$0−$26.3K
MarginsShare of revenue
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22−37017.8%−37378.5%
FY21−26146.5%−25616%
FY20−19678.5%−19497.9%
FY19−17331.5%−17291.3%
FY18−18385.5%−16715.5%
FY17−19972.6%−20769.9%
FY16--
FY15--
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21−$24.3M
FY20−$16.9M
FY19-
FY18-
FY17−$8M
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Citius Pharmaceuticals
  • Healthcare median
−40000%−30000%−20000%−10000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCitius PharmaceuticalsHealthcare median
FY25-−40.6%
FY24-−60.7%
FY23-−97.1%
FY22−37378.5%−128.5%
FY21−25616%−129.2%
FY20−19497.9%−136.5%
FY19−17291.3%−133.7%
FY18−16715.5%−173.4%
FY17−20769.9%−176.7%
FY16-−164.8%
FY15-−183.4%
FY14-−133%
FY13-−88.5%
FY12-−87.4%
FY11-−76.3%

News

No stories filed under Citius Pharmaceuticals yet - coverage appears here as the news feed clusters it.